To examine whether baseline tumor-infiltrating immune cells might predict which NSCLCs are more likely to benefit from CRT and durvalumab, we interrogated immune cell subsets of NSCLCs using multiplex immunofluorescence (mIF) platform (ImmunoProfile) which quantifies CD8, FOXP3, PD-1, and PD-L1. This evidence concerns the gene CD274 and neoplasm.